Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. ====== 💊 Donafenib ====== Donafenib is an oral multikinase inhibitor developed as a targeted therapy for hepatocellular carcinoma (HCC) and other malignancies. It is a structural derivative of sorafenib, modified to improve tolerability and pharmacokinetic properties. 🔬 Mechanism of Action Donafenib inhibits multiple kinases involved in: Tumor cell proliferation (e.g., RAF/MEK/ERK pathway) Angiogenesis (e.g., VEGFR, PDGFR) Tumor microenvironment signaling By blocking these pathways, it reduces both tumor growth and the formation of new blood vessels supplying the tumor. 📈 Clinical Use Indication: Approved in China for unresectable or advanced hepatocellular carcinoma (HCC) Comparison: Shown in clinical trials (e.g., ZGDH3 study) to offer non-inferior survival to sorafenib with fewer adverse events Typical Role: Used as first-line systemic therapy in HCC, especially when tolerability is a concern ⚠️ Adverse Effects Hypertension Hand-foot skin reaction (less frequent than sorafenib) Diarrhea Fatigue Hepatotoxicity (monitor liver function) 📌 Regulatory Status China: Approved since 2021 Other countries: Not yet widely approved or used outside China donafenib.txt Last modified: 2025/06/19 15:53by administrador